Human epididymis protein 4: a novel predictor of ischemic cardiomyopathy

Tang, Yi; Wang, Yinzhen; Xu, Xiaoping; Tu, Laura; Huang, Pei Ching; Yang, Xiaoyan; Li, Lihua; Wu, Juan; Zhang, Yan; Fu, Qinghua; Yu, Yingli; Zheng, Zhaofen; Song, Lixia; Zhang, Yi

doi:10.1186/s12872-021-02319-5

Cited by 4 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results further showed that the ability of HE4 to predict HF after ACS is surprising and promising. Although some studies [41] have shown that renal function deteriorates with increasing levels of HE4 and other studies [42][43][44][45] showed a correlation between HE4 and Cr, our study clarified the independent influence of HE4 after adjusting for confounding factors. Therefore, we believe that HE4 has a potential predictive value and may guide better management of the onset of HF after ACS among women.…”

Section: Discussioncontrasting

confidence: 57%

Serum Human Epididymis Protein 4 as a Prognostic Predictor of New-Onset Heart Failure among Women after Acute Coronary Syndrome: A Single-Center Retrospective Study

Yan¹,

Wu²,

Song³

et al. 2023

Cardiology

View full text Add to dashboard Cite

Introduction: Little is known about the prognostic factors among women with acute coronary syndrome (ACS), partly due to the small number of women included in heart failure (HF) clinical trials. Human epididymis protein 4 (HE4) has been proven to be a new biomarker for acute and chronic HF over the years. We hypothesize that HE4 could be a promising predictor. Methods: This retrospective study analyzed data from Zhejiang Provincial People’s Hospital. This study included 302 female patients with ACS between January 1, 2021, and December 1, 2021. The primary outcome was new-onset HF after ACS during the 12-month follow-up period. We used a logistic regression model to evaluate the association between serum HE4 levels and the incidence of HF. Serum HE4 levels were measured at baseline (within 24 hours after admission). Results: Of the 302 female patients, 70 (23.2 %) developed new-onset HF within 12 months. Serum HE4 levels in patients with adverse events were significantly higher than those in patients without events (8.9 (7.3-11.5) pmol/dL vs. 5.9 (5.0-6.8) pmol/dL, P < 0.001). The levels of HE4, troponin I peak, left ventricular ejection fraction (LVEF), and estimated glomerular filtration rate (eGFR) were validated as independent predictors, with HE4 being the best laboratory predictor (area under the curve, 0.863; 95 % confidence interval, 0.817-0.909). Serum HE4 concentrations of > 6.93 pmol/dL distinguished patients at risk of HF with 82.9 % sensitivity and 78.0 % specificity (maximum Youden index J, 0.609). Moreover, HE4 levels were associated with an increased risk of HF. Discussion/Conclusion: We found a strong relationship between HE4 and the occurrence of HF after ACS among women, which might help identify patients at high risk of HF for whom close or intense management should be mandatory.

show abstract

Section: Discussioncontrasting

confidence: 57%

Serum Human Epididymis Protein 4 as a Prognostic Predictor of New-Onset Heart Failure among Women after Acute Coronary Syndrome: A Single-Center Retrospective Study

Yan¹,

Wu²,

Song³

et al. 2023

Cardiology

View full text Add to dashboard Cite

show abstract

“…Approximately 46% of heart failure patients presented slight increases in HE4, of the order of 300 pmol/L, and this protein was identified as a biomarker of myocardial fibrosis [162]. In patients with effusions, 35% may exhibit HE4 values that are three times above the cut-off point, with levels reaching up to 450 pmol/L [95,160].…”

Section: Human Epididymis Protein 4 (He4)mentioning

confidence: 99%

Factors influencing blood tumor marker concentrations in the absence of neoplasia

Trapé,

Fernández-Galán,

Auge

et al. 2024

TUB

View full text Add to dashboard Cite

BACKGROUND: Tumor markers (TMs) are a heterogeneous group of molecules used in the diagnosis, prognosis and follow-up of cancer patients. During neoplastic differentiation, cells can either directly synthesize or induce the synthesis of TMs, and the release of these molecules into the bloodstream allows their quantification in biological fluids. Although very small concentrations of TMs are usually present in the serum or plasma of healthy subjects, increased concentrations may also be found in the presence of benign diseases or due to technical interference, producing false positive results. MATERIAL AND METHODS AND RESULTS: Our review analyses the causes of false positives described between January 1970 to February 2023 for the TMs most frequently used in clinical practice: α-fetoprotein (AFP), β2-microglobulin (β2-M), cancer antigen 15-3 (CA 15-3), cancer antigen CA 19-9 (CA 19-9), cancer antigen CA 72-4 (CA 72-4), cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), chromogranin A (CgA), choriogonadotropin (hCG), cytokeratin 19 fragment (CYFRA 21-1), neuron-specific enolase (NSE), human epididymis protein 4 (HE4), serum HER2 (sHER2), squamous cell carcinoma antigen (SCCA), protein induced by vitamin K absence-II (PIVKA-II), Pro-gastrin-releasing peptide (Pro-GRP), prostate-specific antigen (PSA), Protein S-100 (S-100) and thyroglobulin (Tg). A total of 247 references were included. CONCLUSIONS: A better understanding of pathophysiological processes and other conditions that affect the concentration of TMs might improve the interpretation of results and their clinical application.

show abstract

“… 9 Our previous research findings demonstrated that HE4 could predict the prognosis in patients with ischemic cardiomyopathy and idiopathic pulmonary hypertension with right heart failure. 10 , 11 In 2013, de Boer et al 12 found that HE4 levels could predict the poor prognosis in patients with AHF. Arnold Piek et al 13 also found that HE4 are associated with heart failure severity in patient with chronic heart failure.…”

Section: Introductionmentioning

confidence: 99%

HE4 Serum Levels are Associated with Poor Prognosis in Patients with Acute Heart Failure Combined with Chronic Kidney Disease

Tang,

Hu,

Liu

et al. 2024

IJGM

Self Cite

View full text Add to dashboard Cite

Purpose The levels of human epididymis protein 4 (HE4) is associated not only with the prognosis of patients with acute heart failure (AHF), but also with chronic kidney disease (CKD). Our study aims to understand the prediction value of HE4 on prognosis in patients with AHF combined with CKD. Patients and Methods This study prospectively enrolled patients diagnosed with AHF combined with CKD at the Department of Cardiology of Hunan Provincial People’s Hospital from March 2019 to December 2022. Serum levels of HE4 were measured using a chemiluminescence microparticle immunoassay. The endpoint events included heart failure readmission and cardiovascular death. Results A total of 130 patients with AHF combined with CKD were included in the stud. The median age is 73 years (interquartile range: 65–79 years). Among the patients, 94 experienced the endpoint events. The multivariable Cox analysis reveals that LnHE4 (HR=2.280, 95% CI 1.300–3.998, P = 0.004) and age (HR=1.024, 95% CI 1.003–1.045, P = 0.025) are independent predictors of the endpoint events. The Kaplan-Meier survival curve demonstrates that patients with HE4 levels>276.15 pmol/L has a significantly higher incidence of endpoint events compared to those with HE4 levels≤276.15 pmol/L (Log rank test: χ2=19.689, P < 0.001). After adjusting for age and gender, the HR is 2.520 (95% CI: 1.626–3.906, P < 0.001). Conclusion HE4 is an independent predictor of heart failure readmission and cardiovascular death in patients with AHF combined with CKD.

show abstract

Human epididymis protein 4: a novel predictor of ischemic cardiomyopathy

Cited by 4 publications

References 17 publications

Serum Human Epididymis Protein 4 as a Prognostic Predictor of New-Onset Heart Failure among Women after Acute Coronary Syndrome: A Single-Center Retrospective Study

Serum Human Epididymis Protein 4 as a Prognostic Predictor of New-Onset Heart Failure among Women after Acute Coronary Syndrome: A Single-Center Retrospective Study

Factors influencing blood tumor marker concentrations in the absence of neoplasia

HE4 Serum Levels are Associated with Poor Prognosis in Patients with Acute Heart Failure Combined with Chronic Kidney Disease

Contact Info

Product

Resources

About